Welcome to our dedicated page for Lixte Biotechnology Hldgs SEC filings (Ticker: LIXTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles the U.S. SEC filings for LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT, LIXTW), a clinical-stage biopharmaceutical company focused on cancer therapies. Through documents such as Forms S-1, S-3 and 8-K, LIXTE provides detailed information on its oncology programs, capital structure, financings and governance.
In its registration statements on Form S-1 and Form S-3, LIXTE outlines its company overview and risk factors, describing a product pipeline centered on protein phosphatase 2A (PP2A) inhibitors and the lead candidate LB-100. These filings explain how LB-100 is being developed to enhance chemotherapy, radiation and immune checkpoint blockade, summarize proof-of-concept clinical trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma, and discuss the company’s reliance on equity financing and stock-based compensation.
Current reports on Form 8-K document material events such as private placements and registered direct offerings of common stock, preferred stock and warrants, entry into Securities Purchase Agreements and Placement Agent Agreements, and related gross proceeds. Other 8-K filings address Board and management changes, the establishment of a Scientific Advisory Committee, publication of scientific findings in Nature that support the LB-100 mechanism, and the company’s initial purchase of digital currencies as part of its updated treasury policy.
These filings also provide insight into LIXTE’s status as a smaller reporting company, its compliance with Nasdaq Capital Market listing rules, and the terms of its outstanding securities, including pre-funded warrants, common stock warrants and preferred stock conversion rights. On Stock Titan, users can access these filings as they are posted to EDGAR and use AI-powered summaries to quickly understand complex sections of registration statements, 8-K disclosures and related exhibits, as well as to review insider-related information where reported on standard SEC forms.
Form 8-K – Item 8.01 (Other Events) filed 11 July 2025 discloses that Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT; warrants LIXTW) issued a 9 July 2025 press release announcing that Nature has published independent research findings that support the scientific rationale underlying the Company’s ongoing Phase II studies in ovarian and colorectal cancers. The Company states that the peer-reviewed article, authored by external physician-scientists, validates the biochemical mechanism targeted by Lixte’s lead compound, thereby reinforcing its clinical development strategy.
There are no financial statements, earnings metrics or transaction details in this filing; the sole purpose is to place the Nature publication on the public record. Management believes the publication may enhance trial enrollment, attract potential partners and improve the Company’s credibility with investors and clinicians, but it does not change the risk profile inherent in early-stage oncology drug development.
- Event date: 9 July 2025 (filed 11 July 2025)
- Affected programs: Ovarian & colorectal cancer trials
- Regulatory status: Unchanged – trials continue; no new FDA submission
- Financial impact: Not quantified; no revenue guidance updated
Overall, the filing is a positive scientific milestone rather than a material financial event, but peer-review validation in a top-tier journal may incrementally strengthen the investment thesis for Lixte’s pipeline.
Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) filed an 8-K reporting that it entered into a Securities Purchase Agreement on 3 July 2025 for a registered direct offering that closed on 8 July 2025.
Transaction terms: the company sold 210,675 common shares and pre-funded warrants covering 763,351 shares at an offering price of $1.54 per share (or $1.53999 per warrant), generating gross proceeds of approximately $1.5 million before deductions.
Placement agent: Spartan Capital Securities, LLC acted as exclusive placement agent, earning a cash fee equal to 8 % of gross proceeds and reimbursement of $40,000 in legal fees under a separate Placement Agent Agreement.
Exhibits: the filing includes the Form of Pre-Funded Warrant (4.1), legal opinion from TroyGould PC (5.1), Securities Purchase Agreement (10.1), Placement Agent Agreement (10.2) and the related press release (99.1).
The report emphasizes that the agreements’ representations and warranties are made solely between the contracting parties and may employ materiality standards different from those of public investors.
FAQ
What is the current stock price of Lixte Biotechnology Hldgs (LIXTW)?
